Health Care·Pharmaceuticals·$276.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.83 | N/A | +1.84% |
management commentary, guidance changes, and full analysis available with Pro.
| +1.84% |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding their earnings performance. However, they did not provide specific guidance for future quarters.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized ongoing commitment to innovation and research.
This earnings report indicates that Merck & Co. Inc. managed to exceed EPS expectations, which might reflect positively on their operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty for investors. The stock reaction is not available, making it difficult to assess market sentiment immediately following the report.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PFIZER INC
Jan 29, 2013